Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,196.34 +15.60 (+0.30%) Dow
38,942.78 +90.51 (+0.23%) Nasdaq
16,384.63 +35.38 (+0.22%) Bitcoin USD
63,825.87 +574.60 (+0.91%) CMC Crypto 200
1,324.08 -41.04 (-3.01%)
Oragenics, Inc. (UAV.F)
| Previous close | 7.5960 |
| Open | N/A |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | N/A - N/A |
| 52-week range | 7.5960 - 7.5960 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 0 |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | -0.00 |
| EPS (TTM) | -6.4800 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireOragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a partnership with Avance Clinical, a leading Contract Research Organization (CRO), to conduct a Phase II clinical trial in Australia. This trial aims to evaluate Oragenics' lead drug candidate, ONP-002, for mild Traumatic Brain Injury (TBI), commonly known as concussion. ONP-002, a novel chemical entity
- Business Wire
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
SARASOTA, Fla., April 19, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April 18, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards. Specifically, the letter states that the Company is not in compliance with the conti
- Business Wire
Oragenics, Inc. Files 10K and Provides Company Update
SARASOTA, Fla., April 01, 2024--Oragenics, Inc. (the "Company") (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has executed on its strategy to diversify its product development portfolio and makes progress in transforming the Company to create long term value. Some key items that have helped to improve t
